Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma

Human Pathology

Volumn 44, Issue 8, 2013, Pages 1465-1471

  Liebscher, Catarina Alisa ^a   Prinzler, Judith ^a   Sinn, Bruno Valentin ^a   Budczies, Jan ^a   Denkert, Carsten ^a   Noske, Aurelia ^b   Sehouli, Jalid ^a   Braicu, Elena Ioana ^a   Dietel, Manfred ^a   Darb Esfahani, Silvia ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ALDH1; EGFR; High grade serous carcinoma; Ovarian; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; HIGH GRADE SEROUS OVARIAN CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

ALDEHYDE DEHYDROGENASE 1; ALDH1; BRCA1; BREAST CANCER ANTIGEN 1; CANCER STEM CELL; CI; CONFIDENCE INTERVAL; CSC; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; FFPE; FIGO; FORMALIN-FIXED, PARAFFIN-EMBEDDED; H&E; HAZARD RATIO; HEMATOXYLIN AND EOSIN; HGSC; HIGH-GRADE SEROUS CARCINOMA; HR; IMMUNOREACTIVITY SCORE; INTERNATIONAL FEDERATION OF GYNAECOLOGY AND OBSTETRICS; IRS; MAMMARY EPITHELIAL CELLS; MEC; OCTIPS; OS; OVARIAN; OVARIAN CANCER THERAPY INNOVATIVE MODELS PROLONG SURVIVAL; OVERALL SURVIVAL; PROGNOSIS; TISSUE MICROARRAY; TMA; TNBC; TRIPLE-NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINAL DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880333428     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.12.016     Document Type: Article

References (35)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. T. Thigpen, A. duBois, and J. McAlpine First-line therapy in ovarian cancer trials Int J Gynecol Cancer 21 2011 756 762
3. R.J. Kurman, and Ie M. Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2008 151 160
4. R.J. Kurman, and Ie M. Shih Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm Hum Pathol 42 2011 918 931
5. W.G. McCluggage Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis Pathology 43 2011 420 432
6. B.M. Boman, and M.S. Wicha Cancer stem cells: a step toward the cure J Clin Oncol 26 2008 2795 2799
7. S.A. Bapat Human ovarian cancer stem cells Reproduction 140 2010 33 41
8. L. Armstrong, M. Stojkovic, and I. Dimmick Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity Stem Cells 22 2004 1142 1151
9. F. Jiang, Q. Qiu, and A. Khanna Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer Mol Cancer Res 7 2009 330 338
10. E.H. Huang, M.J. Hynes, and T. Zhang Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis Cancer Res 69 2009 3382 3389
11. Y.C. Chen, Y.W. Chen, and H.S. Hsu Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer Biochem Biophys Res Commun 385 2009 307 313
12. C. Kahlert, F. Bergmann, and J. Beck Low expression of aldehyde deyhdrogenase 1a1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer BMC Cancer 11 2011 275
13. C. Ginestier, M.H. Hur, and E. Charafe-Jauffret ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567
14. G. Duester Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid Eur J Biochem 267 2000 4315 4324
15. S. Aebi, R. Kroning, and B. Cenni All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells Clin Cancer Res 3 1997 2033 2038
16. D. Zhang, W.F. Holmes, S. Wu, D.R. Soprano, and K.J. Soprano Retinoids and ovarian cancer J Cell Physiol 185 2000 1 20
17. M.J. Caliaro, C. Marmouget, and S. Guichard Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression Int J Cancer 56 1994 743 748
18. L.N. Burga, H. Hu, and A. Juvekar Loss of brca1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in brca1-mutant mice Breast Cancer Res 13 2011 R30
19. H. Nalwoga, J.B. Arnes, H. Wabinga, and L.A. Akslen Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer Br J Cancer 102 2010 369 375
20. A. Noske, M. Schwabe, and W. Weichert An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas BMC Cancer 11 2011 294
21. S. Deng, X. Yang, and H. Lassus Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers PLoS One 5 2010 e10277
22. C.N. Landen Jr., B. Goodman, and A.A. Katre Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer Mol Cancer Ther 9 2010 3186 3199
23. Y.C. Wang, Y.T. Yo, and H.Y. Lee ALDH1-bright epithelial ovarian cancer cells are associated with CD44, drug resistance, and poor clinical outcome Am J Pathol 180 2012 1159 1169
24. B. Chang, G. Liu, and F. Xue ALDH1 expression correlates with favorable prognosis in ovarian cancers Mod Pathol 22 2009 817 823
25. I.A. Silva, S. Bai, and K. McLean Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival Cancer Res 71 2011 3991 4001
26. I. Kryczek, S. Liu, and M. Roh Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells Int J Cancer 130 2012 29 39
27. L.N. Burga, N.M. Tung, and S.L. Troyan Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers Cancer Res 69 2009 1273 1278
28. D. Bell, A. Berchuck, and M. Birrer Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
29. W.D. Foulkes, J.S. Brunet, and I.M. Stefansson The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 2004 830 835
30. O. Metzger-Filho, A. Tutt, and E. de Azambuja Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 2012 1879 1887
31. S.P. Shah, A. Roth, and R. Goya The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
32. K. Alsop, S. Fereday, and C. Meldrum BRCA mutation frequency and patterns of treatment response in brca mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 2012 2654 2663
33. K.L. Bolton, G. Chenevix-Trench, and C. Goh Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 2012 382 390
34. Q. Sheng, and J. Liu The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer Br J Cancer 104 2011 1241 1245
35. P. de Graeff, A.P. Crijns, and S. de Jong Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159